Adjunctive GLP-1 receptor agonists for cardiometabolic risk in antipsychotic-treated patients: A GRADE-assessed meta-analysis of randomized trials.
Journal of psychopharmacology (Oxford, England) · 2026
Abstract e pubblicazione originale
L’abstract è consultabile nella fonte originale. Non viene ripubblicato qui perché non risulta verificata una licenza compatibile.
Leggi nella fonte originale ↗Parole chiave
HumansGlucagon-Like Peptide-1 Receptor AgonistsAntipsychotic AgentsRandomized Controlled Trials as TopicSchizophreniaCardiometabolic Risk FactorsSemaglutideGlucagon-like peptide-1 receptor agonistsantipsychotic-induced weight gaindopamine/serotonin receptor antagonistmetabolic syndromerandomized controlled trialsschizophrenia
Come citare questo studio
Elsayed S Moubarak, Mohamed S Elgendy, Omar Elkoumi, Ahmed A Ibrahim, AlMothana Manasrah, Jamal Ahmad, Malak A Hassan, Omar ElSayed Rageh, Abdelrahman Aly Mohamed, Amr Elzahaby, Mohamed Abuelazm. (2026). Adjunctive GLP-1 receptor agonists for cardiometabolic risk in antipsychotic-treated patients: A GRADE-assessed meta-analysis of randomized trials.. Journal of psychopharmacology (Oxford, England). DOI: 10.1177/02698811261478625
Consulta la pubblicazione originale ↗